Depression and anxiety disorders often occur together, and antidepressants are often also used to treat anxiety disorders.
TC-5685 is a preclinical product candidate for depression and anxiety disorders. TC-5685 inhibits the activity of one or more forms of the α4β2 NNR and is one of the constituent enantiomers of the racemate TC-2216. We completed a Phase 1 single rising dose clinical trial of TC-2216 in healthy volunteers in the first quarter of 2008. Based on our current budget management plans, we do not expect that we will progress the development of TC-5685 or TC-2216 in 2009. If we elect to continue development in the future, we are likely to elect to develop TC-5685 instead of conducting further clinical development of TC-2216.
Depression/Anxiety
Depression is a severe psychiatric mood disorder. It is characterized by a wide range of symptoms that cause significant impairment in daily functioning, such as persistent despondence, loss of interest in normal activities, changes in appetite, difficulty in sleeping, agitation, apathy or feelings of guilt. The most common forms of depression are major depressive disorder and dysthymia, which is less severe.
Anxiety disorders are generally characterized by symptoms of unfounded chronic, exaggerated worry and tension. There are several different types of anxiety disorders, including panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social phobia and generalized anxiety disorder. People diagnosed with depression are also often diagnosed with an anxiety disorder.